Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Alamar Biosciences, Inc. focuses on developing innovative diagnostic solutions for infectious diseases, leveraging proprietary technology to enhance accuracy and speed in testing. The company's competitive position is strengthened by its unique platform that integrates advanced molecular diagnostics with user-friendly interfaces, primarily targeting healthcare providers in North America.
Alamar generates revenue primarily through its diagnostic testing services, which are priced at a premium due to their accuracy and rapid turnaround times. The company also engages in R&D collaborations with pharmaceutical firms, providing a steady stream of income while leveraging its proprietary technology.
FDA approvals for new diagnostic tests
Partnership announcements with major healthcare providers
Changes in reimbursement rates for diagnostic services
Market expansion into Europe and Asia
Regulatory changes impacting diagnostic testing approvals
Technological disruption from competitors developing faster or cheaper tests
Emergence of new competitors with similar or superior technology
Price competition from established diagnostic firms
Negative operating cash flow impacting liquidity
Potential need for future capital raises to fund R&D
moderate - As a biotechnology firm, Alamar's performance is somewhat tied to healthcare spending, which correlates with GDP growth and consumer spending.
Interest rates affect Alamar's cost of capital for R&D investments and may influence healthcare spending; higher rates could compress valuation multiples.
minimal - The company has a negative debt/equity ratio, indicating no reliance on external debt financing.
growth - Investors are likely attracted to Alamar for its potential in the rapidly expanding diagnostics market.
high - The stock has exhibited significant volatility due to its early-stage growth profile and reliance on regulatory approvals.
